Sex ratio, female/male | 0.96 |
Mean age (± SD) | 65 (± 10) |
Mean BMI (± SD) | 23.6 (± 4.16) |
< 18.5 (%) | 37 (8.2) |
18.5–24.9 (%) | 282 (62.1) |
25–29.9 (%) | 105 (23.1) |
≥ 30 (%) | 30 (6.6) |
Performance status at diagnosis | |
0–1 (%) | 397 (87.4) |
2–3 (%) | 58 (12.6) |
Weight loss | |
Weight loss at diagnosis (%) | 294 (64.8) |
Continuous weight loss at restaging (%) | 60 (13.2) |
Jaundice (%) | 264 (58.1) |
Biliary stenting (%) | 272 (59.9) |
Abdominal pain (%) | 293 (64.5) |
Mean CA 19-9 serum level (UI)(±SD) | |
At diagnosis (after jaundice resolution) | 1648 (± 6020) |
Tumor location | |
Head (%) | 315 (69.4) |
Body (%) | 102 (22.5) |
Tail (%) | 37 (8.1) |
Tumor staging | |
Borderline | 336 (74) |
Locally advanced | 118 (26) |
Induction treatment (%) | 454 (100) |
Chemotherapy (%) | 375 (82.6) |
Chemoradiation (%) | 79 (17.4) |
Resection (%) | 142 (31.3) |